Killing tumor cells with a visualized system is a promising strategy in tumor therapy to achieve minimal side effects and high efficiency. Herein, a theranostic nanomedicine (AuNCs-Pt) is developed based on nanocarrier gold nanoclusters (AuNCs) with bifunctions of both NIR-I/NIR-II imaging and glutathione-scavenging abilities. AuNCs-Pt possesses NIR-II imaging capability on a fatal highgrade serous ovarian cancer (HGSOC) model in the deep abdomen, thus facilitating it to be a promising tool for monitoring platinum transportation. Meanwhile, AuNCs-Pt depletes intracellular glutathione to minimize platinum detoxification, effectively maximizing the chemotherapeutic efficacy of platinum. AuNCs-Pt is used to eradicate the tumor burden in this study on a HGSOC model and a patient-derived tumor xenograft model of hepatocellular carcinoma, suggesting great potential for clinical visualized therapy and platinum drug sensitization.

By combining upconversion nanoparticles with the cisplatin (IV) prodrug we have demonstrated that a stable and multifunctional drug delivery system can be designed that will both reduce the drawbacks of cisplatin and give insight in to its in vitro/in vivo imaging. The up/down-conversion fluorescence are detectable and show obvious co-localization, demonstrating that the nanoparticles are rather stable inside cells and retain the UCNPs and block copolymer.